BTK Inhibitor

Leah SherwoodChronic Lymphocytic Leukemia | February 1, 2023
Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting.
Cecilia BrownChronic Lymphocytic Leukemia | February 1, 2023
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Kerri FitzgeraldPrint | November 22, 2022
Because WM is considered incurable, an important treatment consideration is optimization of quality of life.
Advertisement
Cecilia BrownChronic Lymphocytic Leukemia | February 1, 2023
Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL.
Leah SherwoodChronic Lymphocytic Leukemia | February 1, 2023
The FDA has approved the new tablet formulation of acalabrutinib for CLL, SLL, and R/R MCL.
Leah SherwoodChronic Lymphocytic Leukemia | February 1, 2023
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib.
Advertisement
Cecilia BrownMantle Cell Lymphoma | February 8, 2024
Ibrutinib combined with standard chemoimmunotherapy significantly prolonged progression-free survival in older patients.
Leah SherwoodChronic Lymphocytic Leukemia | February 1, 2023
This article discusses managing the most difficult cases of CLL.
Leah LawrenceIndolent B-Cell Lymphoma | June 23, 2022
The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients.
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
Advertisement
Advertisement
Editorial Board